Processa Pharmaceuticals, Inc.: Form 10-Q/A for the period ended Jun 30, 2013
Filed with the SEC on Sep 6, 2013 and accepted by EDGAR at Sep 6, 2013, 16:14 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-04-01 to 2013-06-30 | $97.3k | us-gaap:Revenues |
| Revenue | 6 months2013-01-01 to 2013-06-30 | $116.5k | us-gaap:Revenues |
| Cost of revenue | 3 months2013-04-01 to 2013-06-30 | $61.5k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2013-01-01 to 2013-06-30 | $73.7k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2013-04-01 to 2013-06-30 | $35.8k | us-gaap:GrossProfit |
| Gross profit | 6 months2013-01-01 to 2013-06-30 | $42.8k | us-gaap:GrossProfit |
| Research and development | 3 months2013-04-01 to 2013-06-30 | $63.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2013-01-01 to 2013-06-30 | $135.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2013-04-01 to 2013-06-30 | $665.6k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2013-01-01 to 2013-06-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2013-04-01 to 2013-06-30 | −$33.8k | us-gaap:InterestExpense |
| Interest expense | 6 months2013-01-01 to 2013-06-30 | −$49.6k | us-gaap:InterestExpense |
| Net income | 3 months2013-04-01 to 2013-06-30 | −$726.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-01-01 to 2013-06-30 | −$1.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-04-01 to 2013-06-30 | −$0.34 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2013-01-01 to 2013-06-30 | −$0.79 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2013-01-01 to 2013-06-30 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2013-01-01 to 2013-06-30 | $7.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-06-30 | $629.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-06-30 | $937.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2013-06-30 | $3.5m | us-gaap:Assets |
| Current liabilities | At period end2013-06-30 | $2.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-06-30 | $2.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-06-30 | $1.0m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2013-06-30 | 7,029,397 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001393905-13-000498. Last ingested by Listed: Nov 14, 2026, 23:30 ET. Listed shows no prices and gives no investment advice.